AAPL315.33-0.89 (-0.28%) ▼|ABBV247.98-1.94 (-0.77%) ▼|ABT93.91-0.49 (-0.52%) ▼|ACN135.22-3.84 (-2.76%) ▼|ADBE223.64+0.99 (+0.44%) ▲|AMAT602.50+13.84 (+2.35%) ▲|AMD557.89+11.17 (+2.04%) ▲|AMGN363.39-0.23 (-0.06%) ▼|AMT168.57+3.57 (+2.16%) ▲|AMZN245.34-1.70 (-0.69%) ▼|AVGO399.97-1.14 (-0.28%) ▼|AXP350.58+3.86 (+1.11%) ▲|BA222.28-0.83 (-0.37%) ▼|BAC59.65+0.40 (+0.68%) ▲|BKNG178.39+2.87 (+1.64%) ▲|BLK1,036.08+16.40 (+1.61%) ▲|BMY57.56-0.38 (-0.66%) ▼|BNY151.93-0.33 (-0.22%) ▼|BRK-B493.81-1.64 (-0.33%) ▼|C140.60+1.03 (+0.74%) ▲|CAT951.67+13.28 (+1.42%) ▲|CL92.26+1.25 (+1.37%) ▲|CMCSA23.57+0.23 (+0.96%) ▲|COF201.42+1.32 (+0.66%) ▲|COP109.02+1.00 (+0.93%) ▲|COST916.25+3.28 (+0.36%) ▲|CRM163.36+0.86 (+0.53%) ▲|CSCO121.31+3.00 (+2.54%) ▲|CVS104.18+1.37 (+1.33%) ▲|CVX176.35+2.30 (+1.32%) ▲|DE586.82-6.08 (-1.03%) ▼|DHR198.93+2.95 (+1.51%) ▲|DIS95.62-0.55 (-0.57%) ▼|DUK125.48+0.22 (+0.17%) ▲|EMR138.84+1.04 (+0.75%) ▲|FDX314.71+3.87 (+1.25%) ▲|GD374.81+0.21 (+0.06%) ▲|GE359.40+0.36 (+0.10%) ▲|GEV1,091.19+15.93 (+1.48%) ▲|GILD129.83-5.01 (-3.72%) ▼|GM77.85+1.20 (+1.57%) ▲|GOOG355.03-1.21 (-0.34%) ▼|GOOGL357.18-1.71 (-0.48%) ▼|GS1,055.34-0.63 (-0.06%) ▼|HD343.41+4.68 (+1.38%) ▲|HON226.42+3.00 (+1.34%) ▲|IBM287.61-7.69 (-2.60%) ▼|INTC109.84-2.70 (-2.40%) ▼|INTU274.96+1.58 (+0.58%) ▲|ISRG406.78-4.77 (-1.16%) ▼|JNJ257.03-2.07 (-0.80%) ▼|JPM336.42+0.95 (+0.28%) ▲|KO83.49+0.86 (+1.03%) ▲|LIN529.79+4.23 (+0.80%) ▲|LLY1,188.01-28.94 (-2.38%) ▼|LMT523.48+5.22 (+1.01%) ▲|LOW211.63-1.37 (-0.64%) ▼|LRCX350.33-2.84 (-0.80%) ▼|MA526.55+3.35 (+0.64%) ▲|MCD274.60-1.90 (-0.69%) ▼|MDLZ58.83+0.53 (+0.91%) ▲|MDT83.85+1.46 (+1.77%) ▲|META669.21+37.73 (+5.97%) ▲|MMM157.54+2.20 (+1.42%) ▲|MO71.77+0.18 (+0.25%) ▲|MRK123.55-1.52 (-1.22%) ▼|MS222.26+0.13 (+0.06%) ▲|MSFT385.10+0.74 (+0.19%) ▲|MU979.30-12.34 (-1.24%) ▼|NEE87.96+0.86 (+0.99%) ▲|NFLX73.37-2.10 (-2.78%) ▼|NKE44.38+1.60 (+3.74%) ▲|NOW107.69-1.15 (-1.06%) ▼|NVDA210.96+8.18 (+4.03%) ▲|ORCL140.69-3.04 (-2.11%) ▼|PEP137.38-0.48 (-0.35%) ▼|PFE24.19-0.07 (-0.27%) ▼|PG147.02+0.17 (+0.12%) ▲|PLTR126.79-2.25 (-1.74%) ▼|PM181.61+0.44 (+0.24%) ▲|QCOM189.16-1.95 (-1.02%) ▼|RTX195.94+0.74 (+0.38%) ▲|SBUX106.01-0.40 (-0.38%) ▼|SCHW103.13+1.22 (+1.19%) ▲|SO95.61+0.44 (+0.46%) ▲|SPG218.87-0.84 (-0.38%) ▼|T21.13+0.37 (+1.77%) ▲|TMO527.01+2.30 (+0.44%) ▲|TMUS187.61+6.13 (+3.38%) ▲|TSLA407.76+1.21 (+0.30%) ▲|TXN311.46+2.93 (+0.95%) ▲|UBER74.54+0.19 (+0.26%) ▲|UNH424.63-7.06 (-1.63%) ▼|UNP287.09+2.05 (+0.72%) ▲|UPS112.51+1.77 (+1.60%) ▲|USB62.42+0.52 (+0.83%) ▲|V348.98+0.78 (+0.22%) ▲|VZ42.11+0.58 (+1.39%) ▲|WFC87.12+0.21 (+0.24%) ▲|WMT113.90+1.69 (+1.51%) ▲|XOM138.83+1.37 (+1.00%) ▲|AAPL315.33-0.89 (-0.28%) ▼|ABBV247.98-1.94 (-0.77%) ▼|ABT93.91-0.49 (-0.52%) ▼|ACN135.22-3.84 (-2.76%) ▼|ADBE223.64+0.99 (+0.44%) ▲|AMAT602.50+13.84 (+2.35%) ▲|AMD557.89+11.17 (+2.04%) ▲|AMGN363.39-0.23 (-0.06%) ▼|AMT168.57+3.57 (+2.16%) ▲|AMZN245.34-1.70 (-0.69%) ▼|AVGO399.97-1.14 (-0.28%) ▼|AXP350.58+3.86 (+1.11%) ▲|BA222.28-0.83 (-0.37%) ▼|BAC59.65+0.40 (+0.68%) ▲|BKNG178.39+2.87 (+1.64%) ▲|BLK1,036.08+16.40 (+1.61%) ▲|BMY57.56-0.38 (-0.66%) ▼|BNY151.93-0.33 (-0.22%) ▼|BRK-B493.81-1.64 (-0.33%) ▼|C140.60+1.03 (+0.74%) ▲|CAT951.67+13.28 (+1.42%) ▲|CL92.26+1.25 (+1.37%) ▲|CMCSA23.57+0.23 (+0.96%) ▲|COF201.42+1.32 (+0.66%) ▲|COP109.02+1.00 (+0.93%) ▲|COST916.25+3.28 (+0.36%) ▲|CRM163.36+0.86 (+0.53%) ▲|CSCO121.31+3.00 (+2.54%) ▲|CVS104.18+1.37 (+1.33%) ▲|CVX176.35+2.30 (+1.32%) ▲|DE586.82-6.08 (-1.03%) ▼|DHR198.93+2.95 (+1.51%) ▲|DIS95.62-0.55 (-0.57%) ▼|DUK125.48+0.22 (+0.17%) ▲|EMR138.84+1.04 (+0.75%) ▲|FDX314.71+3.87 (+1.25%) ▲|GD374.81+0.21 (+0.06%) ▲|GE359.40+0.36 (+0.10%) ▲|GEV1,091.19+15.93 (+1.48%) ▲|GILD129.83-5.01 (-3.72%) ▼|GM77.85+1.20 (+1.57%) ▲|GOOG355.03-1.21 (-0.34%) ▼|GOOGL357.18-1.71 (-0.48%) ▼|GS1,055.34-0.63 (-0.06%) ▼|HD343.41+4.68 (+1.38%) ▲|HON226.42+3.00 (+1.34%) ▲|IBM287.61-7.69 (-2.60%) ▼|INTC109.84-2.70 (-2.40%) ▼|INTU274.96+1.58 (+0.58%) ▲|ISRG406.78-4.77 (-1.16%) ▼|JNJ257.03-2.07 (-0.80%) ▼|JPM336.42+0.95 (+0.28%) ▲|KO83.49+0.86 (+1.03%) ▲|LIN529.79+4.23 (+0.80%) ▲|LLY1,188.01-28.94 (-2.38%) ▼|LMT523.48+5.22 (+1.01%) ▲|LOW211.63-1.37 (-0.64%) ▼|LRCX350.33-2.84 (-0.80%) ▼|MA526.55+3.35 (+0.64%) ▲|MCD274.60-1.90 (-0.69%) ▼|MDLZ58.83+0.53 (+0.91%) ▲|MDT83.85+1.46 (+1.77%) ▲|META669.21+37.73 (+5.97%) ▲|MMM157.54+2.20 (+1.42%) ▲|MO71.77+0.18 (+0.25%) ▲|MRK123.55-1.52 (-1.22%) ▼|MS222.26+0.13 (+0.06%) ▲|MSFT385.10+0.74 (+0.19%) ▲|MU979.30-12.34 (-1.24%) ▼|NEE87.96+0.86 (+0.99%) ▲|NFLX73.37-2.10 (-2.78%) ▼|NKE44.38+1.60 (+3.74%) ▲|NOW107.69-1.15 (-1.06%) ▼|NVDA210.96+8.18 (+4.03%) ▲|ORCL140.69-3.04 (-2.11%) ▼|PEP137.38-0.48 (-0.35%) ▼|PFE24.19-0.07 (-0.27%) ▼|PG147.02+0.17 (+0.12%) ▲|PLTR126.79-2.25 (-1.74%) ▼|PM181.61+0.44 (+0.24%) ▲|QCOM189.16-1.95 (-1.02%) ▼|RTX195.94+0.74 (+0.38%) ▲|SBUX106.01-0.40 (-0.38%) ▼|SCHW103.13+1.22 (+1.19%) ▲|SO95.61+0.44 (+0.46%) ▲|SPG218.87-0.84 (-0.38%) ▼|T21.13+0.37 (+1.77%) ▲|TMO527.01+2.30 (+0.44%) ▲|TMUS187.61+6.13 (+3.38%) ▲|TSLA407.76+1.21 (+0.30%) ▲|TXN311.46+2.93 (+0.95%) ▲|UBER74.54+0.19 (+0.26%) ▲|UNH424.63-7.06 (-1.63%) ▼|UNP287.09+2.05 (+0.72%) ▲|UPS112.51+1.77 (+1.60%) ▲|USB62.42+0.52 (+0.83%) ▲|V348.98+0.78 (+0.22%) ▲|VZ42.11+0.58 (+1.39%) ▲|WFC87.12+0.21 (+0.24%) ▲|WMT113.90+1.69 (+1.51%) ▲|XOM138.83+1.37 (+1.00%) ▲|
29.8 C
New York
Friday, July 10, 2026

Tag: access

newssourceFORcompanyinformationcontent1releasesmarket

New data demonstrates robust efficacy of Vyepti® (eptinezumab) in otherwise difficult-to-treat patients with severe migraine

The full results of the phase IV RESOLUTION trial were presented at the European Academy of Neurology 2025 Annual Congress, where Vyepti® (eptinezumab) demonstrated...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

New data from phase III trial confirms efficacy of Vyepti® (eptinezumab) in Asian population with chronic migraine

The full results of the phase III registrational SUNRISE trial were presented at the European Academy of Neurology 2025 Annual Congress, where eptinezumab demonstrated statistically...

Bitcoin Solaris Announces Final Presale Phase Ahead of July Launch

Bitcoin Solaris

TALLINN, Estonia, June 21, 2025 (GLOBE NEWSWIRE) -- Bitcoin Solaris (BTC-S), a next-generation blockchain project, has officially entered the final stages of its highly anticipated presale. With its public launch set for July 31, 2025, the momentum around BTC-S is building rapidly as thousands of users secure early access to what many are calling one of the most accessible and performance-driven blockchain ecosystems of the year.

BTC-S: Where Scalability Meets Accessibility

IIM Udaipur Concludes Executive Education Training Program for PM SHRI School Principals in Collaboration with RSSP Jaipur

UDAIPUR, India, June 21, 2025 /PRNewswire/ -- Indian Institute of Management Udaipur (IIM Udaipur), in collaboration with the Rajasthan School Shiksha Parishad (RSSP), Jaipur,...

William Stern’s Cardiff Redefines Working Capital for Small Businesses

Cardiff CEO William Stern is modernizing the merchant cash advances (MCA) concept, also known as Revenue Based Financing. SAN DIEGO, June 21, 2025 /PRNewswire/ -- Traditional...

ICPO Foundation co-founded the RLT Angels Association with the aim of growing access to Radiotheranostics to one million patients

Further founding members include the European Association of Nuclear Medicine (EANM), GE HealthCare, Novartis, and RayzeBio, a Bristol Myers Squibb company.

$255 Payday Loans Online Same Day No Credit Check Bad Credit Launched by Viva Payday Loans

Viva Payday Loans now offers $255 payday loans online same day with optional no credit check, delivering fast, transparent emergency cash support.

MountBay Energy Unlocks Microbial Biofilm Technology to Revolutionize Battery Longevity

NEW YORK, June 21, 2025 (GLOBE NEWSWIRE) -- MountBay Energy has unveiled groundbreaking research on microbial biofilms that could redefine the future of grid-scale energy storage. The study, led by founder Vrushabhraj Tanawade, introduces a bio-integrated insulation method using thermophilic and mesophilic microbial consortia to regulate heat inside battery modules. The results are striking: up to a 22% reduction in internal temperature and a 30% improvement in carbon lifecycle efficiency.

Saudi Arabia Concludes Landmark BIO 2025 Debut as Kingdom Opens Doors to Global Biotech Collaboration

From genomics to regulatory innovation, the Kingdom’s presence in Boston establishes it as a major partner in global health science 
From genomics to regulatory innovation, the Kingdom’s presence in Boston establishes it as a major partner in global health science

Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more...

Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA

Novo Nordisk’s subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025

Bagsværd, Denmark, 20 June 2025 – Novo Nordisk announces subcutaneous amycretin data being presented at the American Diabetes Association (ADA) 85th Scientific Sessions in Chicago, US.1 Full results of two clinical trials evaluating the safety, tolerability and weight loss potential of subcutaneous and oral amycretin in people with overweight or obesity were published today in The Lancet medical journal.1,3 Amycretin is the first treatment that combines GLP-1 and amylin receptor agonism biology in a single molecule.

Embrace Active Site Care Patch Becomes First Medical Device Clinically Proven to Significantly Improve Lipohypertrophy (LH) in Insulin-Using Diabetes Patients

Findings from 16-week trial of novel compression patch will be shared for the first time at the 85th Scientific Sessions of the American Diabetes...

Studies show promising results for individuals with type 2 diabetes and young children with type 1 diabetes on MiniMed™ 780G system

Data supports the potential of future indication expansion for the MiniMed™ 780G system. LENNY trial results published in Lancet Diabetes & Endocrinology. GALWAY, Ireland and...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsAccess

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers